RxDoctor Payments Data

Patrick Matoole, MD

Neurology · Indianapolis, INNPI 1588668149

Payments from drug & device makers

$13,697in general payments, 2019–2025

Across 719 payments — averaging $19.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novartis$1K
  • Biogen$1K
  • UCB, Inc.$982
  • Eisai Inc.$548
  • MDD US Operations, LLC$525
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$13,685100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)94$1,476
Novartis81$1,199
Biogen45$1,020
UCB, Inc.44$982
Eisai Inc.26$548
MDD US Operations, LLC16$525
Jazz Pharmaceuticals Inc.18$519
Neurocrine Biosciences, Inc.23$439
Lilly USA, LLC24$398
Amgen(2 entities)21$391
SK Life Science, Inc.14$362
Supernus Pharmaceuticals, Inc.19$345
AstraZeneca(2 entities)16$295
Harmony Biosciences LLC11$282
Pfizer15$280
Lundbeck LLC12$258
Genentech USA, Inc.13$254
Amneal Pharmaceuticals LLC14$220
Argenx US, Inc.11$211
EMD Serono, Inc.30$204
Acadia Pharmaceuticals Inc13$202
Sanofi10$196
Kyowa Kirin, Inc.9$195
Teva Pharmaceuticals USA, Inc.13$194
Bristol Myers Squibb9$160
Grifols USA, LLC7$159
Catalyst Pharmaceuticals, Inc.5$159
Biohaven Pharmaceutical Holding Company Ltd.6$140
Alnylam Pharmaceuticals Inc.5$135
Johnson & Johnson6$133
Vanda Pharmaceuticals Inc.6$131
Greenwich Biosciences, Inc.8$128
Medtronic1$118
TG Therapeutics, Inc.5$103
Biohaven Pharmaceuticals, Inc.5$99
Neurelis, Inc.4$86
Avanir Pharmaceuticals, Inc.4$72
Sunovion Pharmaceuticals Inc.4$70
Banner Life Sciences, LLC3$65
Livanova USA, Inc.4$63
CSL Behring3$59
Scilex Pharmaceuticals Inc.3$55
Springworks Therapeutics, Inc.2$54
Tanabe Pharma America, Inc.3$54
Octapharma USA, Inc.1$49
Sumitomo Pharma America, Inc.2$49
Aprecia Pharmaceuticals, LLC3$47
Impel Pharmaceuticals Inc.2$45
Takeda Pharmaceuticals U.S.A., Inc.2$44
Mallinckrodt Hospital Products Inc.2$43
E.r. Squibb & Sons, L.L.C.2$42
Acorda Therapeutics, Inc2$40
Otsuka America Pharmaceutical, Inc.2$34
Idorsia Pharmaceuticals US Inc2$32
Adamas Pharmaceuticals, Inc.2$27
Avadel CNS Pharmaceuticals, LLC1$26
Abbott2$26
Almatica Pharma LLC2$25
Sanofi-aventis U.S. LLC1$23
Boston Scientific1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,697 in reported general payments places this provider in the 70th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$923,502
Medicare patients
464
Services billed
23,487

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZeposiaOzanimod Hydrochloride30$264,910
RytaryCarbidopa/Levodopa18$33,216
KeppraLevetiracetam14$32,853
LamictalLamotrigine14$31,688
AptiomEslicarbazepine Acetate12$29,103
Pregabalin120$5,870
Rivastigmine36$5,595
Fentanyl18$5,351
SavellaMilnacipran Hcl11$5,273
Lacosamide70$4,698
Memantine Hcl ErMemantine Hcl98$4,359
Levetiracetam150$4,105
Duloxetine Hcl177$3,937
Gabapentin174$3,390
Carbidopa-LevodopaCarbidopa/Levodopa171$2,504

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Zeposia$42$264,91030 claims
Amneal Pharmaceuticals LLCRytary, Mycophenolate Mofetil$220$33,71230 claims
Sunovion Pharmaceuticals Inc.Aptiom$70$29,10312 claims
AbbVieSavella$1,476$5,27311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 308 neurology providers in Indiana.

Other neurology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →